Jack Nielsen resigns from board; Aligos out of compliance with Nasdaq Audit Committee rule

Aligos Therapeutics, Inc.

Director Jack Nielsen resigned effective May 21, 2024 for personal reasons; no disagreement with company.
Audit Committee now has two members; Nasdaq requires three under Rule 5605(c)(2)(A).
Company notified Nasdaq of non-compliance on May 22, 2024 and plans to cure within 180-day period.
Aligos intends to appoint a qualified third director to Audit Committee within the cure period.

item 3.01 item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Jack Nielsen

Director

ALGS · Aligos Therapeutics, Inc.

Filed: May 22, 2024, 7:59 PM ET

The Company intends to appoint to the Audit Committee a third director who satisfies the criteria for service on the Audit Committee no later than 180 days after Mr. Nielsen’s resignation.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.9

Jack Nielsen resigned as Director at Aligos Therapeutics, Inc..

Action: resigned
Role: Director

Exact text from the filing

The Company intends to appoint to the Audit Committee a third director who satisfies the criteria for service on the Audit Committee no later than 180 days after Mr. Nielsen’s resignation.

View on SEC.gov

Aligos Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-144929

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.